Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Brief Summary

Official Title: “An Extension Open-Label Safety Study of a 24-month 20 mg Dose Regimen of Tasimelteon for the Treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception Who Have Enrolled in Other Tasimelteon Clinical Trials”

The purpose of this study is to evaluate the safety of tasimelteon in male and female patients who suffer from Non-24-Hour Sleep-Wake Disorder.

  • Study Type: Interventional
  • Study Design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
  • Study Primary Completion Date: January 2015

Detailed Clinical Trial Description

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier is < 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping. As time progresses, the endogenous circadian rhythm of sleep-wake propensity in these individuals moves further and further away from the 24-hour light-dark cycle and gradually, these individuals are unable to sleep at night and as a result experience extreme sleepiness during the daytime hours and more frequent naps with a longer duration. Eventually, the sleep-wake time moves back into alignment with the social time for sleep and the individuals sleep well at night and have decreased daytime napping. The alignment between their endogenous circadian rhythms and the 24-hour day is temporary as they are continually drifting later and later each day.

The study is comprised of one 24-month treatment phase, as all subjects enrolled in the trial have already been diagnosed with N24HSWD. Frequency of study visits will depend on the subject's prior length of exposure to tasimelteon; accordingly, subjects will be assigned to one of two groups upon enrollment into the study. The short-term exposure group will consist of subjects for which it is possible at screening that they have been exposed to tasimelteon for less than 6 months. The long-term exposure group will consist of subjects who have more than 6 months of exposure to tasimelteon.

After completion of the 24-month treatment phase, subjects have the option to enroll into the optional open-label extension sub-study for an additional 52 weeks. Frequency of visits will be identical regardless of previous exposure (short term/long term).

Interventions Used in this Clinical Trial

  • Drug: tasimelteon
    • 20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: tasimelteon
    • 20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension

Outcome Measures for this Clinical Trial

Primary Measures

  • Number of participants with Treatment-Emergent Adverse Events (AEs)
    • Time Frame: 24 months + 12 month optional extension
      Safety Issue?: Yes

Secondary Measures

  • Number of participants with changes in Clinical Laboratory Data
    • Time Frame: 24 months + 12 month optional extension
      Safety Issue?: Yes
  • Number of participants with newly occurring or worsening ECG abnormalities
    • Time Frame: 24 months + 12 month optional extension
      Safety Issue?: Yes
  • Number of participants with clinically notable Vital Signs and Body Measurements
    • Time Frame: 24 months + 12 month optional extension
      Safety Issue?: Yes
  • Number of participants who report a positive result for the Columbia Suicide Severity Rating Scale (C-SSRS)
    • Time Frame: 24 months + 12 month optional extension
      Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Inclusion Criteria

1. Ability and acceptance to provide informed consent;

2. Men or women at least 18 years of age or older who meet one of the following:

  • Has enrolled in VP-VEC-162-3201 (with sponsor approval)
  • Has completed VP-VEC-162-3203
  • Was deemed a non-responder in VP-VEC-162-3203
  • Has enrolled in VP-VEC-162-3203 (with sponsor approval)
  • Has a previous diagnosis of N24HSWD
  • The subject is totally blind and meets the following Diagnostic and Statistical Manual of Mental Disorders 5 diagnostic criteria
  • A persistent or recurrent pattern of sleep disruption that is primarily due to an alteration of the circadian system or to a misalignment between the endogenous circadian rhythm and the sleep-wake schedule required by an individual's physical environment or social or professional schedule.
  • The sleep disruption leads to excessive sleepiness or insomnia, or both.
  • The sleep disturbance causes clinically significant distress or impairment in social, occupational, and other important areas of functioning.

Specifically: A pattern of sleep-wake cycles that is not synchronized to the 24-hour environment, with a consistent daily drift (usually to later and later times) of sleep onset and wake times.

3. For US participants only: Males, non-fecund females (i.e., surgically sterilized,if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control for a period of 35 days before the first dosing during the study and for one month following the last dose and must have a negative pregnancy test at the screening and baseline visits Note: Women using hormonal methods of birth control must use an additional method of birth control during the study and for one month after the last dose.

4. Diagnosis of N24HSWD in a previous tasimelteon study;

5. Willing and able to comply with study requirements and restrictions;

Exclusion Criteria

1. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;

2. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;

3. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 40g/day);

4. Patients having any current suicidal ideation of type 4 or 5 on the C-SSRS at Screening or Baseline;

5. Patient is at risk of suicide, in the opinion of the Investigator. Evidence of suicide risk could include any suicide attempt within the past year or any other suicidal behavior within the past year;

6. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;

7. Clinically significant deviation from normal in vital signs measurements, or physical examination findings at screening or baseline as determined by the clinical investigator;

8. Pregnant or lactating females;

9. Smoke more than 10 cigarettes/day;

10. Exposure to any investigational drug other than tasimelteon, including placebo, within 30 days, 5 half-lives, or the exclusion period given by a previous study in which the patient has participated in, whichever of the three scenarios is longer.

11. Unwilling or unable to discontinue usage of medication listed in Section 8.2.1;

12. Any other sound medical reason as determined by the clinical investigator.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Vanda Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Vanda Pharmaceuticals, Study Director, Vanda Pharmaceuticals
  • Overall Contact(s)
    • Vanda Pharmaceuticals, 1-877-486-4817

Source

Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01429116